期刊文献+

正在进行的晚期胰腺癌临床试验 被引量:8

Clinical Trials on Advanced-Stage Pancreatic Cancer
下载PDF
导出
摘要 吉西他滨30分钟静脉滴注是晚期胰腺癌的标准治疗方案。为了更好的提高吉西他滨的疗效和改善胰腺癌患者的预后,临床上正在进行各种试验:更改用药方法;与其它化疗药物联合应用或替换为更有效的化合物。本文以互连网上注册的临床试验数据库(www.clinicaltrials.gov)为主要来源,检索了目前美国已注册的、正在进行的有关胰腺癌的临床试验,将其略作整理分类作一综述。 Gemcitabine (iv over 30 minutes) is the standard therapy for inoperable pancreatic cancer of advanced stage. In order to improve the effect of gemcitabine and the prognosis of pancreatic cancer, lots of clinical trials are being conducted, i.e. to change the method of administration, combine with other drugs, or to be replaced by other more efficient drugs. The article summarizes the ongoing clinical trials in American at present, that can be searched at data base of the clinical trials on internet (www.clinicahrials.gov).
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2005年第20期1197-1199,共3页 Chinese Journal of Clinical Oncology
关键词 胰腺肿瘤 药物 台疗 临床试验 吉西他滨 Pancreatic cancer Clinical trials Gemcitabine Chemotherapy
  • 相关文献

参考文献16

  • 1梁汉霖,王羽,谢德荣.姑息化疗和最佳支持治疗在晚期胰腺癌中的比较[J].循证医学,2004,4(1):9-13. 被引量:3
  • 2梁汉霖,王羽,谢德荣,郭双双.5-FU联合与5-FU单药治疗晚期胰腺癌比较的Meta分析[J].肿瘤防治杂志,2005,12(11):858-863. 被引量:3
  • 3Burris HA 3rd,Moore MJ,Andersen J,et at.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403~2413.
  • 4Ishii H.Furuse J.Nagase M.Yoshino M.Impact of gemcitabine on the treatment of metastatic pancreatic cancer[J].J Gastroenterol Hepatol,2005,20(1):62~66.
  • 5Scheithauer W,Schull B,Ulrich-Pur H,et at.Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma:a randomized phase Ⅱ trial[J].Ann Oncol,2003,14(1):97~104.
  • 6Colucci G,Giuliani F,Gebbia V,et at.Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma:a prospective,randomized phase Ⅲ study of the Gruppo Oncologia dell'Italia Meridionale [J] Cancer,2002,94(4):902~910.
  • 7Bramhall SR,Schulz J.Nemunaitis J,et at.A double-blind placebo-controlled,randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer[J].BrJ Cancer,2002,87(2):161~167.
  • 8Tempero M,Plunkett W,Ruiz van Haperen V,et al.Randomized phase Ⅱ comparison of dose-intense gemcitabine:thirtyminute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma [J].J Clin Oncol,2003,21(18):3402~3408.
  • 9Fossella FV,Lippman SM,Shin DM,et al.Maximum-tolerated dose defined for single-agent gemcitabine:A phase Ⅰ dose-escalation study in chemotherapy-native patients with advanced nonsmall-cell lung cancer[J].J Clin Oncol,1997,15(1):310~316.
  • 10Shewach DS,Lawrence TS.It's What's Inside That Counts [J].J Clin Oncol,2003,21(18):3383~3384.

二级参考文献54

  • 1龚德根,郑鸿.健择联用HCPT治疗胰腺癌的临床观察[J].中华腹部疾病杂志,2003,3(8):570-571. 被引量:1
  • 2王奇璐.胰腺癌[A].孙燕主编.内科肿瘤学[C].北京:人民卫生出版社,2001.630-631.
  • 3[1]Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial [J]. J Clin Oncol, 1997, 15:2403-2413.
  • 4[2]Berlin JD, Catalano P,Thomas JP, et al. Phase Ⅲ study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma. Eastern Cooperative Oncology Group Trial E2297 [J]. J Clin Oncol,2002, 20: 3270-3275.
  • 5[3]Evans JD, Stark A, Johnson CD, et al. A phase Ⅱ trial of marimastat in advanced pancreatic cancer [J]. Br J Cancer,2001,85:1865-1870.
  • 6[4]Zujewski J,Horak ID, Bol C J, et al. Phase Ⅰ and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer [J]. J Clin Oncol, 2000, 18:927-941.
  • 7[5]Adjei AA, Erlichman C, Davis JN, et al. A phase Ⅰ trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity [ J ]. Cancer Res, 2000,60:1871-1877.
  • 8[6]Patnaik A, Eckhardt S, Izbicka E, et al. A phase Ⅰ and pharmacokinetic (PK) study of the farnesyltransferase inhibitor,R115777 in combination with gemcitabine (Gem) [C]. Proc Annu Meet Am Soc Clin Oncol, 2000, 5A. Abstract.
  • 9[7]Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase Ⅱ study of anti-epidermal growth factor receptor(EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer[C]. Proc Annu Meet Am Soc Clin Oncol, 2001,518. Abstract.
  • 10[8]Hidalgo M, Siu LL, Nemunaitis J, et al. Phase Ⅰ and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J]. J Clin Oncol, 2001, 19:3267-3279.

共引文献29

同被引文献27

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部